Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivomixx for Bone Loss in AI-Treated Breast Cancer
NCT03518268Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jan 2019
- Primary completion
- Apr 2021
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Collagen type 1 cross-linked C-telopeptide at 6 months and Serum type 1 procollagen (N-terminal) at 6 months. Status: unknown.
Beyond the preview
Go deeper on NCT03518268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518268.